Major advances in cardiovascular medicine have been driven by innovations in basic research in biological and technical sciences. Despite the clear evidence regarding the treatments that have been demonstrated to be useful to improve patients' outcomes, their transferability to everyday clinical practice seems to be at least suboptimal. The European Society of Cardiology (ESC), therefore, planned to support a program, denominated EuroHeart, for continuous data collection of standardized and/or harmonized variables in common cardiovascular diseases, such as ACS, HF and A Fib. EuroHeart is an observational, prospective, multicentre initiative with continuous data collection in consecutive patients with ACS, HF and A Fib to support continuous quality of care improvement through the evaluation of quality indicators (QIs) defined by the ESC. All patients included in the EuroHeart initiative, will enter a 12 month longitudinal follow-up with the collection of clinical events and clinical status data.
Study Type
OBSERVATIONAL
Enrollment
5,000
EuroHeart is an initiative of the European Society of Cardiology (ESC) supporting continuous quality-of-care improvement through individual patient data collection. The present registry component refers specifically to the Italian implementation of the EuroHeart programme, aimed at monitoring and improving adherence to ESC quality indicators within Italian clinical practice.
Ospedale Valdarno S. Maria Della Gruccia - U.O. Malattie Cardiovascolari
Montevarchi, AREZZO, Italy
RECRUITINGOspedale Miulli - U.O.C. Cardiologia - Utic
Acquaviva delle Fonti, BA, Italy
RECRUITINGOspedale Della Murgia - Fabio Perinei - S.C. Cardiologia-Utic
Altamura, BA, Italy
RECRUITINGOspedale San Paolo - Cardiologia-Utic
Bari, BA, Italy
Adherence to ESC Quality indicators (STEMI patients reperfused)
Proportion of patients with STEMI reperfused among those eligible (onset of symptoms to diagnosis \<12 hours)
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (STEMI patients reperfused <90 min)
Proportion of patients with STEMI who receive timely reperfusion with PCI (wire crossing) within 90 minutes from initial diagnostic ECG
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (coronary angiography in NSTEMI patients within 24 hours)
Rate of NSTEMI patients who receive invasive within 24 hours from their diagnosis
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (radial access)
Use of radial access in case of invasive strategy for patients with STEMI and NSTEMI
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (time to reperfusion in STEMI patients)
The time between the initial STEMI diagnosis and arterial access (absolute value) for primary PCI
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (pre-discharge LVEF evaluation in STEMI and NSTEMI patients)
The proportion of patients with STEMI and NSTEMI who have an assessment of their left ventricular ejection fraction (LVEF) before hospital discharge
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (in hospital LDL-c evaluation in STEMI and NSTEMI patients)
The proportion of patients with STEMI and NSTEMI who have their LDL cholesterol measured during hospitalization
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (DAPT prescription at discharge in STEMI and NSTEMI patients)
Proportion of patients with STEMI and NSTEMI discharged on dual antiplatelet therapy
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (LLA prescription at discharge in STEMI and NSTEMI patients)
Proportion of patients discharged from hospital on Lipid Lowering Agents (LLA)
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (ACEi/ARB/ARNI prescription at discharge in patients with LVEF ≤40%)
Proportion of patients with LVEF ≤40% who are discharged from hospital on angiotensin converting enzymes inhibitors (ACEi) or angiotensin receptor blockers (ARBs) or angiotensin receptor-neprilysin inhibitor (ARNI)
Time frame: From enrollment to 12 months follow-up
Adherence to ESC Quality indicators (Beta blockers prescription at discharge in patients with LVEF ≤40%)
Proportion of patients with LVEF ≤40% who are discharged from hospital on beta blockers.
Time frame: From enrollment to 12 months follow-up
Cardiovascular and non-cardiovascular events during follow-up
Proportion of patients with clinical events at 12 months
Time frame: 12 months follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ospedale Di Venere - U.O.C. Di Cardiologia
Bari, BA, Italy
RECRUITINGAsst Spedali Civili - Cardiologia
Brescia, BS, Italy
RECRUITINGA.O.U. Cagliari Policlinico Monserrato - Sc Cardiologia Utic Emodinamica
Monserrato, CAGLIARI, Italy
ACTIVE_NOT_RECRUITINGAzienda Ospedaliera Cannizzaro - Uoc Cardiologia
Catania, CATANIA, Italy
RECRUITINGOspedale A. Cardarelli - U.O. Cardiologia E Utic
Campobasso, CB, Italy
RECRUITINGAzienda Ospedaliera S. Anna E S. Sebastiano - U.O. Cardiologia D'Emergenza Con Utic
Caserta, CE, Italy
RECRUITING...and 47 more locations